Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer.

Suchy SL, Hancher LM, Wang D, Ervin PR Jr, Brower SL.

Cancer Biol Ther. 2011 Jun 15;11(12):1059-64. Epub 2011 Jun 15.

PMID:
21525781
[PubMed - indexed for MEDLINE]
Free Article
2.

An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab.

Rice SD, Cassino TR, Sakhamuri L, Song N, Williams KE, Brower SL.

Cancer Biol Ther. 2011 Jan 15;11(2):196-203. Epub 2011 Jan 15.

PMID:
20980824
[PubMed - indexed for MEDLINE]
Free Article
3.

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, Kalofonos HP.

Invest New Drugs. 2010 Oct;28(5):554-60. doi: 10.1007/s10637-009-9290-0. Epub 2009 Jul 15.

PMID:
19603143
[PubMed - indexed for MEDLINE]
4.

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

Adams VR, Leggas M.

Clin Ther. 2007 Jul;29(7):1338-53. Review.

PMID:
17825686
[PubMed - indexed for MEDLINE]
5.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
[PubMed - indexed for MEDLINE]
6.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

PMID:
20103629
[PubMed - indexed for MEDLINE]
Free Article
7.

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

Bousquet G, Varna M, Ferreira I, Wang L, Mongiat-Artus P, Leboeuf C, de Bazelaire C, Faivre S, Bertheau P, Raymond E, Germain S, Janin A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1183-93. doi: 10.1007/s00280-013-2300-0. Epub 2013 Sep 24.

PMID:
24061866
[PubMed - indexed for MEDLINE]
8.

The ChemoFx assay: an ex vivo cell culture assay for predicting anticancer drug responses.

Ochs RL, Burholt D, Kornblith P.

Methods Mol Med. 2005;110:155-72.

PMID:
15901934
[PubMed - indexed for MEDLINE]
9.

Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.

Canter D, Kutikov A, Golovine K, Makhov P, Simhan J, Uzzo RG, Kolenko VM.

Can J Urol. 2011 Aug;18(4):5819-25.

PMID:
21854714
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.

Catena R, Luis-Ravelo D, Antón I, Zandueta C, Salazar-Colocho P, Larzábal L, Calvo A, Lecanda F.

Cancer Res. 2011 Jan 1;71(1):164-74. doi: 10.1158/0008-5472.CAN-10-1708. Epub 2010 Nov 19.

PMID:
21097719
[PubMed - indexed for MEDLINE]
Free Article
11.

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD.

Mol Cancer Ther. 2008 May;7(5):1110-20. doi: 10.1158/1535-7163.MCT-07-2218.

PMID:
18483300
[PubMed - indexed for MEDLINE]
Free Article
12.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

PMID:
19417025
[PubMed - indexed for MEDLINE]
Free Article
13.

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Jul;51(1):42-8. doi: 10.1002/pbc.21535.

PMID:
18293383
[PubMed - indexed for MEDLINE]
14.

Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay.

Rice SD, Heinzman JM, Brower SL, Ervin PR, Song N, Shen K, Wang D.

Anticancer Res. 2010 Jul;30(7):2805-11.

PMID:
20683016
[PubMed - indexed for MEDLINE]
15.

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

Kancha RK, Grundler R, Peschel C, Duyster J.

Exp Hematol. 2007 Oct;35(10):1522-6.

PMID:
17889720
[PubMed - indexed for MEDLINE]
16.

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM.

Clin Cancer Res. 2011 Dec 1;17(23):7337-46. doi: 10.1158/1078-0432.CCR-11-1667. Epub 2011 Oct 6. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):318.

PMID:
21980135
[PubMed - indexed for MEDLINE]
Free Article
17.

Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.

Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.

J Oncol Pharm Pract. 2007 Mar;13(1):5-15. Review.

PMID:
17621562
[PubMed - indexed for MEDLINE]
18.

Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.

Schem C, Bauerschlag D, Bender S, Lorenzen AC, Loermann D, Hamann S, Rösel F, Kalthoff H, Glüer CC, Jonat W, Tiwari S.

BMC Cancer. 2013 Jan 24;13:32. doi: 10.1186/1471-2407-13-32.

PMID:
23347638
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.

Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C.

Eur J Cancer. 2012 Aug;48(12):1831-41. doi: 10.1016/j.ejca.2012.01.032. Epub 2012 Mar 3.

PMID:
22391574
[PubMed - indexed for MEDLINE]
20.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk